Example: bankruptcy
New Zealand Data Sheet - Medsafe
New Zealand Data Sheet . In vitro, Levetiracetam and its primary metabolite have been shown not to inhibit the major human liver cytochrome P. 450
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.euEach film-coated tablet contains 250 mg levetiracetam. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM
LEVETIRACETAM 250 MG, 500 MG, 750 MG AND …
www.mhra.gov.ukUKPAR – Levetiracetam 250mg, 500mg, 750mg & 1000 mg Film-Coated Tablets Tablets PL 14017/0228-0231 -2 - LEVETIRACETAM 250 MG, 500 MG…
LEVETIRACETAM Keppra® Vial 100 mg/mL, …
www.segurneo.esLEVETIRACETAM Keppra® Vial 100 mg/mL, solución v.o. 100 mg/mL y comprimidos 250 y 500 mg DOSIS 10 mg/Kg/dosis v.o., i.v. en 15 min a concentración 5 mg/mL Ajustar dosis según necesidad cada 1-2 sem
MATERIAL SAFETY DATA SHEET - Lupin …
www.lupinpharmaceuticals.comMSDS : 033/01 Page 3 of 6 Effective Date : 30/01/2014 6.
Post-Operative Instructions for Patients after …
www.sd-neurosurgeon.comPost-Operative Instructions for Patients after Craniotomy Here are some suggestions for care after a craniotomy (head operation). We realize that it is impossible to anticipate all of the questions or problems that may